Clinical Trial Detail

NCT ID NCT01603212
Title Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Aldesleukin + Alpha 2 Interferon + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST